{"id":"https://openalex.org/W4291397341","doi":"https://doi.org/10.1002/hon.3066","title":"A phase 1 study of ruxolitinib, steroids and lenalidomide for relapsed/refractory multiple myeloma patients","display_name":"A phase 1 study of ruxolitinib, steroids and lenalidomide for relapsed/refractory multiple myeloma patients","publication_year":2022,"publication_date":"2022-08-10","ids":{"openalex":"https://openalex.org/W4291397341","doi":"https://doi.org/10.1002/hon.3066","pmid":"https://pubmed.ncbi.nlm.nih.gov/35946431"},"language":"en","primary_location":{"id":"doi:10.1002/hon.3066","doi":"https://doi.org/10.1002/hon.3066","is_oa":false,"landing_page_url":"https://doi.org/10.1002/hon.3066","pdf_url":null,"source":{"id":"https://openalex.org/S23714410","display_name":"Hematological Oncology","issn_l":"0278-0232","issn":["0278-0232","1099-1069"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Hematological Oncology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5040835019","display_name":"James R. Berenson","orcid":"https://orcid.org/0000-0003-1587-6104","observed_orcids":["https://orcid.org/0000-0003-1587-6104"]},"institutions":[{"id":"https://openalex.org/I4210111451","display_name":"Oncotherapeutics (United States)","ror":"https://ror.org/01s33dn56","country_code":"US","type":"company","lineage":["https://openalex.org/I4210111451"]},{"id":"https://openalex.org/I4210151813","display_name":"Institute for Myeloma & Bone Cancer Research","ror":"https://ror.org/04xwmf991","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210151813"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"James R. Berenson","raw_affiliation_strings":["Berenson Cancer Center, West Hollywood, Los Angeles, California, USA","Institute for Myeloma and Bone Cancer Research, West Hollywood, Los Angeles, California, USA","Oncotherapeutics, West Hollywood, Los Angeles, California, USA"],"raw_orcid":"https://orcid.org/0000-0003-1587-6104","affiliations":[{"raw_affiliation_string":"Berenson Cancer Center, West Hollywood, Los Angeles, California, USA","institution_ids":[]},{"raw_affiliation_string":"Institute for Myeloma and Bone Cancer Research, West Hollywood, Los Angeles, California, USA","institution_ids":["https://openalex.org/I4210151813"]},{"raw_affiliation_string":"Oncotherapeutics, West Hollywood, Los Angeles, California, USA","institution_ids":["https://openalex.org/I4210111451"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023637763","display_name":"Clara T. Kim","orcid":"https://orcid.org/0009-0009-0655-274X","observed_orcids":["https://orcid.org/0009-0009-0655-274X"]},"institutions":[{"id":"https://openalex.org/I4210111451","display_name":"Oncotherapeutics (United States)","ror":"https://ror.org/01s33dn56","country_code":"US","type":"company","lineage":["https://openalex.org/I4210111451"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Clara Kim","raw_affiliation_strings":["Oncotherapeutics, West Hollywood, Los Angeles, California, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncotherapeutics, West Hollywood, Los Angeles, California, USA","institution_ids":["https://openalex.org/I4210111451"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084603634","display_name":"Sean Elliott Bujarski","orcid":"https://orcid.org/0009-0006-7994-7660","observed_orcids":["https://orcid.org/0009-0006-7994-7660"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sean Bujarski","raw_affiliation_strings":["Berenson Cancer Center, West Hollywood, Los Angeles, California, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Berenson Cancer Center, West Hollywood, Los Angeles, California, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"Jennifer To","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210111451","display_name":"Oncotherapeutics (United States)","ror":"https://ror.org/01s33dn56","country_code":"US","type":"company","lineage":["https://openalex.org/I4210111451"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jennifer To","raw_affiliation_strings":["Oncotherapeutics, West Hollywood, Los Angeles, California, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncotherapeutics, West Hollywood, Los Angeles, California, USA","institution_ids":["https://openalex.org/I4210111451"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068437316","display_name":"Tanya Magazinnik Spektor","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210111451","display_name":"Oncotherapeutics (United States)","ror":"https://ror.org/01s33dn56","country_code":"US","type":"company","lineage":["https://openalex.org/I4210111451"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Tanya M. Spektor","raw_affiliation_strings":["Oncotherapeutics, West Hollywood, Los Angeles, California, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncotherapeutics, West Hollywood, Los Angeles, California, USA","institution_ids":["https://openalex.org/I4210111451"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5008684736","display_name":"Daisy Martinez","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210111451","display_name":"Oncotherapeutics (United States)","ror":"https://ror.org/01s33dn56","country_code":"US","type":"company","lineage":["https://openalex.org/I4210111451"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Daisy Martinez","raw_affiliation_strings":["Oncotherapeutics, West Hollywood, Los Angeles, California, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncotherapeutics, West Hollywood, Los Angeles, California, USA","institution_ids":["https://openalex.org/I4210111451"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073126599","display_name":"Carley Turner","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210111451","display_name":"Oncotherapeutics (United States)","ror":"https://ror.org/01s33dn56","country_code":"US","type":"company","lineage":["https://openalex.org/I4210111451"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Carley Turner","raw_affiliation_strings":["Oncotherapeutics, West Hollywood, Los Angeles, California, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncotherapeutics, West Hollywood, Los Angeles, California, USA","institution_ids":["https://openalex.org/I4210111451"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111709630","display_name":"Matthew Ghermezi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210111451","display_name":"Oncotherapeutics (United States)","ror":"https://ror.org/01s33dn56","country_code":"US","type":"company","lineage":["https://openalex.org/I4210111451"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Matthew Ghermezi","raw_affiliation_strings":["Oncotherapeutics, West Hollywood, Los Angeles, California, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncotherapeutics, West Hollywood, Los Angeles, California, USA","institution_ids":["https://openalex.org/I4210111451"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064758797","display_name":"Benjamin Eades","orcid":"https://orcid.org/0000-0002-4150-7786","observed_orcids":["https://orcid.org/0000-0002-4150-7786"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Benjamin M. Eades","raw_affiliation_strings":["Berenson Cancer Center, West Hollywood, Los Angeles, California, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Berenson Cancer Center, West Hollywood, Los Angeles, California, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5021554856","display_name":"Regina A. Swift","orcid":"https://orcid.org/0000-0002-0367-5965","observed_orcids":["https://orcid.org/0000-0002-0367-5965"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Regina A. Swift","raw_affiliation_strings":["Berenson Cancer Center, West Hollywood, Los Angeles, California, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Berenson Cancer Center, West Hollywood, Los Angeles, California, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5006913373","display_name":"Gary K. Schwartz","orcid":"https://orcid.org/0000-0003-1813-5061","observed_orcids":["https://orcid.org/0000-0003-1813-5061"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Gary Schwartz","raw_affiliation_strings":["Berenson Cancer Center, West Hollywood, Los Angeles, California, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Berenson Cancer Center, West Hollywood, Los Angeles, California, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031848378","display_name":"Shahrooz Eshaghian","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Shahrooz Eshaghian","raw_affiliation_strings":["Compassionate Care Research Group, Fountain Valley, Los Angeles, California, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Compassionate Care Research Group, Fountain Valley, Los Angeles, California, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"Robert A. Moss","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Robert A. Moss","raw_affiliation_strings":["F.A.C.P., Inc, Fountain Valley, Los Angeles, California, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"F.A.C.P., Inc, Fountain Valley, Los Angeles, California, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111792159","display_name":"Stephen Wong Lim","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1282927834","display_name":"Cedars-Sinai Medical Center","ror":"https://ror.org/02pammg90","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1282927834"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Stephen Lim","raw_affiliation_strings":["Cedars-Sinai Medical Center, Los Angeles, California, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cedars-Sinai Medical Center, Los Angeles, California, USA","institution_ids":["https://openalex.org/I1282927834"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5108763799","display_name":"Robert Allen Vescio","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1282927834","display_name":"Cedars-Sinai Medical Center","ror":"https://ror.org/02pammg90","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1282927834"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Robert Vescio","raw_affiliation_strings":["Cedars-Sinai Medical Center, Los Angeles, California, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cedars-Sinai Medical Center, Los Angeles, California, USA","institution_ids":["https://openalex.org/I1282927834"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5040835019"],"corresponding_institution_ids":["https://openalex.org/I4210111451","https://openalex.org/I4210151813"],"apc_list":{"value":4100,"currency":"USD","value_usd":4100},"apc_paid":null,"fwci":1.6131,"has_fulltext":false,"cited_by_count":9,"citation_normalized_percentile":{"value":0.84824166,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":97},"biblio":{"volume":"40","issue":"5","first_page":"906","last_page":"913"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11221","display_name":"Bone health and treatments","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/ruxolitinib","display_name":"ruxolitinib","score":0.9890000224113464},{"id":"https://openalex.org/keywords/lenalidomide","display_name":"lenalidomide","score":0.9810000061988831},{"id":"https://openalex.org/keywords/methylprednisolone","display_name":"methylprednisolone","score":0.9100000262260437},{"id":"https://openalex.org/keywords/relapsed-refractory-multiple-myeloma","display_name":"relapsed/refractory multiple myeloma","score":0.9919999837875366},{"id":"https://openalex.org/keywords/jak-inhibitors","display_name":"JAK inhibitors","score":0.8370000123977661},{"id":"https://openalex.org/keywords/lenalidomide-resistance","display_name":"lenalidomide resistance","score":0.9890000224113464},{"id":"https://openalex.org/keywords/muc1","display_name":"MUC1","score":0.9100000262260437},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.6389999985694885},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.8119999766349792},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.5640000104904175},{"id":"https://openalex.org/keywords/sepsis","display_name":"sepsis","score":0.7480000257492065},{"id":"https://openalex.org/keywords/pneumonia","display_name":"pneumonia","score":0.5080000162124634}],"concepts":[{"id":"https://openalex.org/C2776063141","wikidata":"https://www.wikidata.org/wiki/Q425681","display_name":"Lenalidomide","level":3,"score":0.958358883857727},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8116905689239502},{"id":"https://openalex.org/C2776112149","wikidata":"https://www.wikidata.org/wiki/Q7383611","display_name":"Ruxolitinib","level":4,"score":0.7913540601730347},{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.6895698308944702},{"id":"https://openalex.org/C2780401358","wikidata":"https://www.wikidata.org/wiki/Q422252","display_name":"Dexamethasone","level":2,"score":0.600912868976593},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5677220225334167},{"id":"https://openalex.org/C2777478702","wikidata":"https://www.wikidata.org/wiki/Q419319","display_name":"Bortezomib","level":3,"score":0.5096065998077393},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.47839367389678955},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.4625619649887085},{"id":"https://openalex.org/C2779609412","wikidata":"https://www.wikidata.org/wiki/Q203174","display_name":"Thalidomide","level":3,"score":0.450745165348053},{"id":"https://openalex.org/C142424586","wikidata":"https://www.wikidata.org/wiki/Q7307572","display_name":"Refractory (planetary science)","level":2,"score":0.4483475089073181},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.4322763681411743},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.40972745418548584},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.383962482213974},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.33512789011001587},{"id":"https://openalex.org/C2780076729","wikidata":"https://www.wikidata.org/wiki/Q1752571","display_name":"Myelofibrosis","level":3,"score":0.15245875716209412},{"id":"https://openalex.org/C2780007613","wikidata":"https://www.wikidata.org/wiki/Q546523","display_name":"Bone marrow","level":2,"score":0.1363065540790558},{"id":"https://openalex.org/C121332964","wikidata":"https://www.wikidata.org/wiki/Q413","display_name":"Physics","level":0,"score":0.0},{"id":"https://openalex.org/C87355193","wikidata":"https://www.wikidata.org/wiki/Q411","display_name":"Astrobiology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000077269","descriptor_name":"Lenalidomide","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009101","descriptor_name":"Multiple Myeloma","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1002/hon.3066","doi":"https://doi.org/10.1002/hon.3066","is_oa":false,"landing_page_url":"https://doi.org/10.1002/hon.3066","pdf_url":null,"source":{"id":"https://openalex.org/S23714410","display_name":"Hematological Oncology","issn_l":"0278-0232","issn":["0278-0232","1099-1069"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Hematological Oncology","raw_type":"journal-article"},{"id":"pmid:35946431","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/35946431","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Hematological oncology","raw_type":"Clinical Trial, Phase I"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9922999739646912,"display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320317544","display_name":"Incyte","ror":"https://ror.org/00cvzzg84"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":28,"referenced_works":["https://openalex.org/W1575204077","https://openalex.org/W1985864219","https://openalex.org/W1990223118","https://openalex.org/W2009062406","https://openalex.org/W2017166289","https://openalex.org/W2044436186","https://openalex.org/W2049386412","https://openalex.org/W2063355387","https://openalex.org/W2072114878","https://openalex.org/W2075131681","https://openalex.org/W2077334296","https://openalex.org/W2084178693","https://openalex.org/W2086285137","https://openalex.org/W2150518976","https://openalex.org/W2161941551","https://openalex.org/W2164716517","https://openalex.org/W2394652810","https://openalex.org/W2409115115","https://openalex.org/W2417864726","https://openalex.org/W2528329272","https://openalex.org/W2563588839","https://openalex.org/W2692323761","https://openalex.org/W2723748116","https://openalex.org/W2888746916","https://openalex.org/W2896086596","https://openalex.org/W2900068404","https://openalex.org/W2909464822","https://openalex.org/W2912240505"],"related_works":["https://openalex.org/W2999468559","https://openalex.org/W2914485485","https://openalex.org/W2954827306","https://openalex.org/W4251667674","https://openalex.org/W3095300667","https://openalex.org/W4200127932","https://openalex.org/W4389234657","https://openalex.org/W4394989363","https://openalex.org/W4310163207","https://openalex.org/W2912240505"],"abstract_inverted_index":{"Ruxolitinib":[0],"with":[1,49,55,62,222],"lenalidomide":[2,16,50,97,147,217],"and":[3,10,23,45,51,65,69,107,121,136,148,162,166,190,200,218],"dexamethasone":[4],"shows":[5],"anti-myeloma":[6],"effects":[7],"in":[8,11,18,89],"vitro":[9],"vivo.":[12],"MUC1":[13],"leads":[14],"to":[15,33,41,86,150,174,216],"resistance":[17],"multiple":[19],"myeloma":[20],"(MM)":[21],"cells,":[22],"ruxolitinib":[24,29,48,94],"blocks":[25],"its":[26],"expression.":[27],"Thus,":[28],"may":[30],"restore":[31],"sensitivity":[32],"lenalidomide.":[34,175],"A":[35,76],"phase":[36],"I":[37,205],"trial":[38,206],"was":[39,84,133],"conducted":[40],"determine":[42],"the":[43],"safety":[44],"efficacy":[46],"of":[47,102,142],"methylprednisolone":[52,108],"for":[53,220,232],"patients":[54,127,171,221],"relapsed/refractory":[56],"(RR)MM":[57],"who":[58],"had":[59,138],"been":[60],"treated":[61],"lenalidomide,":[63],"steroids":[64,149,219],"a":[66,103,140,209,227],"proteasome":[67],"inhibitor":[68],"showed":[70],"progressive":[71],"disease":[72],"at":[73],"study":[74],"entry.":[75],"traditional":[77],"3":[78,80,177],"+":[79],"dose":[81,156],"escalation":[82],"design":[83],"used":[85],"enroll":[87],"subjects":[88],"four":[90],"cohorts.":[91],"Subjects":[92],"received":[93,139],"twice":[95],"daily,":[96],"daily":[98],"on":[99],"days":[100],"1-21":[101],"28":[104],"day":[105],"cycle":[106],"orally":[109],"every":[110],"other":[111],"day.":[112],"Primary":[113],"endpoints":[114],"were":[115,128,153,164,172],"safety,":[116],"clinical":[117],"benefit":[118],"rate":[119,124],"(CBR)":[120],"overall":[122],"response":[123],"(ORR).":[125],"Forty-nine":[126],"enrolled.":[129],"The":[130,160],"median":[131,141],"age":[132],"64":[134],"years":[135],"they":[137],"six":[143],"prior":[144],"treatments":[145],"including":[146],"which":[151],"94%":[152],"refractory.":[154],"No":[155],"limiting":[157],"toxicities":[158],"occurred.":[159],"CBR":[161],"ORR":[163],"49%":[165],"36%,":[167],"respectively.":[168],"All":[169],"responding":[170],"refractory":[173],"Grade":[176],"or":[178],"4":[179],"adverse":[180],"events":[181],"(AEs)":[182],"included":[183,197],"anemia":[184],"(17%),":[185],"decreased":[186],"lymphocyte":[187],"count":[188],"(15%),":[189],"hypophosphatemia":[191],"(10%).":[192],"Most":[193],"common":[194],"serious":[195],"AEs":[196],"sepsis":[198],"(9.8%)":[199],"pneumonia":[201],"(7.8%).":[202],"This":[203],"Phase":[204],"demonstrates":[207],"that":[208],"JAK":[210],"inhibitor,":[211],"ruxolitinib,":[212],"can":[213],"overcome":[214],"refractoriness":[215],"RRMM.":[223],"These":[224],"results":[225],"represent":[226],"promising":[228],"novel":[229],"therapeutic":[230],"approach":[231],"treating":[233],"MM.":[234],"NCT03110822.":[235]},"counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":4},{"year":2023,"cited_by_count":3},{"year":2022,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2022-08-15T00:00:00"}